Fostamatinib for treating refractory chronic immune thrombocytopenia

  • Technology appraisal guidance
  • TA835
  • Published: 
Download guidance (PDF)

2 Information about fostamatinib

Marketing authorisation indication

2.1 Fostamatinib (Tavlesse, Grifols) is indicated 'for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for fostamatinib.

Price

2.3 The list prices of fostamatinib are:

  • £3,090 per 60‑tablet pack, each tablet contains 100 mg of fostamatinib (excluding VAT; BNF online, accessed August 2022)

  • £4,635 per 60‑tablet pack, each tablet contains 150 mg of fostamatinib (excluding VAT; BNF online, accessed August 2022).

    The company has a commercial arrangement. This makes fostamatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.